Structural analysis of the glucocorticoid receptor ligand-binding domain in complex with triamcinolone acetonide and a fragment of the atypical coregulator, small heterodimer partner

Molecular Pharmacology

Volumn 92, Issue 1, 2017, Pages 12-21

  Weikum, Emily R ^a   Okafor, C Denise ^a   D'Agostino, Emma H ^a   Colucci, Jennifer K ^a   Ortlund, Eric A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MOMETASONE FUROATE; NUCLEAR RECEPTOR COACTIVATOR 2; SMALL HETERODIMER PARTNER PEPTIDE; TRANSCRIPTION FACTOR; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; CELL RECEPTOR; GLUCOCORTICOID; NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 2;

ARTICLE; BIOCHEMISTRY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; LIGAND BINDING DOMAIN; LXXLL MOTIF; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; RECEPTOR AFFINITY; STRUCTURE ANALYSIS; AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; DOSE RESPONSE; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE;

EID: 85020164683     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.117.108506     Document Type: Article

References (70)

1. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66:213-221.
2. Bain DL, Yang Q, Connaghan KD, Robblee JP, Miura MT, Degala GD, Lambert JR, and Maluf NK (2012) Glucocorticoid receptor-DNA interactions: binding energetics are the primary determinant of sequence-specific transcriptional activity. J Mol Biol 422:18-32.
3. Båvner A, Johansson L, Toresson G, Gustafsson JA, and Treuter E (2002) A transcriptional inhibitor targeted by the atypical orphan nuclear receptor SHP. EMBO Rep 3:478-484.
4. Bikowski J, Pillai R, and Shroot B (2006) The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol 5:125-130.
5. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, et al. (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105.
6. Borgius LJ, Steffensen KR, Gustafsson JA, and Treuter E (2002) Glucocorticoid signaling is perturbed by the atypical orphan receptor and corepressor SHP. J Biol Chem 277:49761-49766.
7. Bridgham JT, Ortlund EA, and Thornton JW (2009) An epistatic ratchet constrains the direction of glucocorticoid receptor evolution. Nature 461:515-519.
8. Carson-Jurica MA, Schrader WT, and O'Malley BW (1990) Steroid receptor family: structure and functions. Endocr Rev 11:201-220.
9. Case D, Babin V, Berryman J, Betz R, Cai Q, Cerutti D, Cheatham Iii T, Darden T, Duke R and Gohlke H (2014) Amber 14. University of California, San Francisco.
10. Case D and Kollman P (2012) AmberTools 12. University of California, San Francisco.
11. Cato AC and Wade E (1996) Molecular mechanisms of anti-inflammatory action of glucocorticoids. BioEssays 18:371-378.
12. Clark AR and Belvisi MG (2012) Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther 134:54-67.
13. Colucci JK and Ortlund EA (2013) X-ray crystal structure of the ancestral 3-ketosteroid receptor-progesterone-mifepristone complex shows mifepristone bound at the coactivator binding interface. PLoS One 8:e80761.
14. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, and Yamamoto KR (1998) Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 12:3343-3356.
15. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, 3rd, Snoeyink J, and Richardson JS et al. (2007) MolProbity: allatom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35:W375-W383.
16. De Bosscher K, Vanden Berghe W, and Haegeman G (2000) Mechanisms of antiinflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 109:16-22.
17. Derendorf H and Meltzer EO (2008) Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 63: 1292-1300.
18. Doggrell SA (2001) Triamcinolone: new and old indications. Expert Opin Pharmacother 2:1177-1186.
19. Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
20. Feig M, Karanicolas J, and Brooks, 3rdCL (2004) MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. J Mol Graph Model 22:377-395.
21. Fredman R and Tenenhaus M (2013) Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Burns 39:549-557.
22. Gebhardt JC, Suter DM, Roy R, Zhao ZW, Chapman AR, Basu S, Maniatis T, and Xie XS (2013) Single-molecule imaging of transcription factor binding to DNA in live mammalian cells. Nat Methods 10:421-426.
23. Gee AC and Katzenellenbogen JA (2001) Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. Mol Endocrinol 15:421-428.
24. Gronemeyer H and Moras D (1995) Nuclear receptors. How to finger DNA. Nature 375:190-191.
25. Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AF, Diederich S, and Bahr V (2004) Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 151: 397-406.
26. Heery DM, Kalkhoven E, Hoare S, and Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736.
27. Hu X and Lazar MA (1999) The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402:93-96.
28. Hudson WH, Youn C, and Ortlund EA (2013) The structural basis of direct glucocorticoid-mediated transrepression. Nat Struct Mol Biol 20:53-58.
29. Jenkins BD, Pullen CB, and Darimont BD (2001) Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol Metab 12:122-126.
30. Johansson L, Båvner A, Thomsen JS, Färnegårdh M, Gustafsson JA, and Treuter E (2000) The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors. Mol Cell Biol 20: 1124-1133.
31. Johansson L, Thomsen JS, Damdimopoulos AE, Spyrou G, Gustafsson JA, and Treuter E (1999) The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ERalpha and ERbeta. J Biol Chem 274:345-353.
32. Joosten RP, Salzemann J, Bloch V, Stockinger H, Berglund AC, Blanchet C, Bongcam- Rudloff E, Combet C, Da Costa AL, Deleage G, et al. (2009) PDB-REDO: automated re-refinement of X-ray structure models in the PDB. J Appl Cryst 42: 376-384.
33. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, and Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926-935.
34. Kadmiel M and Cidlowski JA (2013) Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 34:518-530.
35. Kendall EC (1951) The development of cortisone as a therapeutic agent. Antibiot Chemother (Northfield) 1:7-15.
36. Kohn JA, Deshpande K, and Ortlund EA (2012) Deciphering modern glucocorticoid cross-pharmacology using ancestral corticosteroid receptors. J Biol Chem 287: 16267-16275.
37. Kojetin DJ and Burris TP (2013) Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. Mol Pharmacol 83:1-8.
38. Kumar R and Thompson EB (1999) The structure of the nuclear hormone receptors. Steroids 64:310-319.
39. Lee YK, Dell H, Dowhan DH, Hadzopoulou-Cladaras M, and Moore DD (2000) The orphan nuclear receptor SHP inhibits hepatocyte nuclear factor 4 and retinoid X receptor transactivation: two mechanisms for repression. Mol Cell Biol 20:187-195.
40. Lee YS, Chanda D, Sim J, Park YY, and Choi HS (2007) Structure and function of the atypical orphan nuclear receptor small heterodimer partner. Int Rev Cytol 261:117-158.
41. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, and Sigler PB (1991) Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352:497-505.
42. Macchiarulo A, Rizzo G, Costantino G, Fiorucci S, and Pellicciari R (2006) Unveiling hidden features of orphan nuclear receptors: the case of the small heterodimer partner (SHP). J Mol Graph Model 24:362-372.
43. McDonald IK and Thornton JM (1994) Satisfying hydrogen bonding potential in proteins. J Mol Biol 238:777-793.
44. Millard CJ, Watson PJ, Fairall L, and Schwabe JW (2013) An evolving understanding of nuclear receptor coregulator proteins. J Mol Endocrinol 51:T23-T36.
45. Mordacq JC and Linzer DI (1989) Co-localization of elements required for phorbol ester stimulation and glucocorticoid repression of proliferin gene expression. Genes Dev 3:760-769.
46. Musille PM, Pathak MC, Lauer JL, Hudson WH, Griffin PR, and Ortlund EA (2012) Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation. Nat Struct Mol Biol 19:532-537.
47. Nagy L and Schwabe JW (2004) Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 29:317-324.
48. Nehmé A, Lobenhofer EK, Stamer WD, and Edelman JL (2009) Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics 2:58.
49. Nicholls RA, Fischer M, McNicholas S, and Murshudov GN (2014) Conformationindependent structural comparison of macromolecules with ProSMART. Acta Crystallogr D Biol Crystallogr 70:2487-2499.
50. O'Malley BW and Tsai MJ (1992) Molecular pathways of steroid receptor action. Biol Reprod 46:163-167.
51. Ortlund EA, Bridgham JT, Redinbo MR, and Thornton JW (2007) Crystal structure of an ancient protein: evolution by conformational epistasis. Science 317:1544-1548.
52. Ortlund EA, Lee Y, Solomon IH, Hager JM, Safi R, Choi Y, Guan Z, Tripathy A, Raetz CR, McDonnell DP, et al. (2005) Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP. Nat Struct Mol Biol 12:357-363.
53. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
54. Pérez A, Marchán I, Svozil D, Sponer J, Cheatham, 3rdTE, Laughton CA, and Orozco M (2007) Refinement of the AMBER force field for nucleic acids: improving the description of a/g conformers. Biophys J 92:3817-3829.
55. Pratt WB and Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360.
56. Robblee JP, Miura MT, and Bain DL (2012) Glucocorticoid receptor-promoter interactions: energetic dissection suggests a framework for the specificity of steroid receptor-mediated gene regulation. Biochemistry 51:4463-4472.
57. Roe DR and Cheatham, 3rdTE (2013) PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9: 3084-3095.
58. Ryckaert J-P, Ciccotti G, and Berendsen HJ (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:327-341.
59. Sacta MA, Chinenov Y, and Rogatsky I (2016) Glucocorticoid Signaling: An Update from a Genomic Perspective. Annu Rev Physiol 78:155-180.
60. Schäcke H, Döcke WD, and Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43.
61. Schüle R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, Verma IM, and Evans RM (1990) Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62:1217-1226.
62. Seol W, Choi HS, and Moore DD (1996) An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 272:1336-1339.
63. Srinivasan S, Nwachukwu JC, Parent AA, Cavett V, Nowak J, Hughes TS, Kojetin DJ, Katzenellenbogen JA, and Nettles KW (2013) Ligand-binding dynamics rewire cellular signaling via estrogen receptor-a. Nat Chem Biol 9:326-332.
64. Thiruchelvam PT, Lai CF, Hua H, Thomas RS, Hurtado A, Hudson W, Bayly AR, Kyle FJ, Periyasamy M, Photiou A, et al. (2011) The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat 127:385-396.
65. Vandevyver S, Dejager L, and Libert C (2014) Comprehensive overview of the structure and regulation of the glucocorticoid receptor. Endocr Rev 35:671-693.
66. Veritti D, Di Giulio A, Sarao V, and Lanzetta P (2012) Drug safety evaluation of intravitreal triamcinolone acetonide. Expert Opin Drug Saf 11:331-340.
67. Weikum ER, Knuesel MT, Ortlund EA, and Yamamoto KR (2017) Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat Rev Mol Cell Biol 18:159-174.
68. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, and Karin M (1990) Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62: 1205-1215.
69. Yoneda Y, Han D, Ogita K, and Watanabe A (1995) Distinction between binding of [3H]triamcinolone acetonide to a ligand binding domain on the glucocorticoid receptor complex in cytosol fractions of brain and liver from the rat with intact adrenals. Brain Res 685:105-116.
70. Zhi X, Zhou XE, He Y, Zechner C, Suino-Powell KM, Kliewer SA, Melcher K, Mangelsdorf DJ, and Xu HE (2014) Structural insights into gene repression by the orphan nuclear receptor SHP. Proc Natl Acad Sci USA 111:839-844.